rs4473653 — SLC2A9

SLC2A9 rs4473653 — A Third Independent Signal for Renal Urate Control

The SLC2A9 gene is the single largest genetic determinant of serum uric acid levels in humans, encoding GLUT9¹¹ GLUT9
Glucose Transporter 9, a high-capacity urate transporter in the kidney proximal tubule that reabsorbs urate from the tubular filtrate back into the bloodstream at rates 45–60-fold faster than glucose. What is less widely appreciated is that the SLC2A9 locus contains several genetically independent signals — distinct intronic haplotype blocks, each contributing its own additive effect on renal urate handling. rs4473653 sits at chromosome 4 position 9,969,434 (GRCh38), roughly 8 kb from rs11942223 (another independent signal already in the database) and in a separate haplotype block from both rs11942223 and the coding variant rs3733591 (Arg265His).

The A allele at rs4473653 (the GRCh38 reference allele) tags a haplotype associated with reduced renal urate excretion and elevated steady-state serum uric acid. Its striking rarity in East Asian populations (~11% G-allele frequency, versus ~64% in Africans) mirrors the population pattern seen across SLC2A9 protective variants — where ancestries with the lowest frequency of the protective allele have the highest population burden of gout and hyperuricemia.

The Mechanism

rs4473653 is an intron variant that does not change the GLUT9 protein sequence. Its functional effect is regulatory in nature, consistent with the observation by Wei et al. 2014²² observation by Wei et al. 2014
Wei et al. Abundant local interactions in the 4p16.1 region suggest functional mechanisms underlying SLC2A9 associations. Hum Mol Genet, 2014 that epistatically interacting SNPs at the SLC2A9 locus are enriched at active enhancers in hepatic (HepG2, P = 4.7 × 10⁻⁵) and precursor red blood (K562, P = 5.0 × 10⁻⁶) cells, putatively regulating SLC2A9 transcription. Intronic variants in this region can influence how much GLUT9 protein the kidney produces, thereby modifying the efficiency of urate reabsorption even without changing the transporter's structure.

The G allele is protective: carriers have somewhat higher GLUT9-mediated urate excretion (or lower reabsorption), translating to modestly lower serum uric acid at steady state. The A allele (major allele in most populations) maintains standard or slightly elevated urate reabsorption, raising the urate setpoint. As with all SLC2A9 intronic variants, the effect is substantially larger in women than men³³ substantially larger in women than men
Döring et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008, where estrogen's independent stimulation of renal urate excretion amplifies the phenotypic contrast between genotypes (1.2% variance explained in men vs. up to 6% in women).

The Evidence

Multiple independent signals at the SLC2A9 locus: The SLC2A9 gene region on chromosome 4p16.1 harbours complex genetic architecture. Conditional GWAS analyses have consistently identified multiple statistically independent association signals within the gene's introns, collectively explaining substantially more urate variance than any single lead SNP alone. Wei et al. (2014)⁴⁴ Wei et al. (2014) demonstrated using ARIC and Framingham Heart Study data that a forward-selection model of local interactions at 4p16.1 explained 1.5% more urate variance beyond the single lead SNP, with the interacting variants enriched at functional enhancer elements. The implication is that multiple intronic haplotypes — likely including the block tagged by rs4473653 — independently regulate SLC2A9 expression in metabolically relevant tissues.

Sex-stratified effects across the SLC2A9 locus: The pronounced sex-specific effect at this locus is the most replicated finding in SLC2A9 genetics. Döring et al. (2008)⁵⁵ Döring et al. (2008) showed that intronic SLC2A9 variants explain up to 6% of serum urate variance in women but only 1.2% in men, with each protective minor allele copy reducing uric acid by 0.23–0.36 mg/dL in mixed European cohorts. The mechanism is an interaction between estrogen signalling and renal urate transporters: estrogen independently upregulates fractional excretion of urate, creating a hormonal buffer that makes the genetic signal more visible in women. This buffer is lost at menopause.

Fructose interaction: A fructose challenge study in 76 participants from three ethnic groups demonstrated that SLC2A9 genotype modulates the acute serum urate spike after consuming 64 g of fructose. In European Caucasian participants, carriers of the protective SLC2A9 allele showed a significantly attenuated hyperuricaemic response and higher fractional excretion of uric acid after the fructose load, while this protective effect was not seen in Māori or Pacific Island participants (Dalbeth et al., 2013)⁶⁶ (Dalbeth et al., 2013). This gene-environment interaction confirms that dietary fructose — from sugar-sweetened beverages and concentrated fruit juices — is the highest-leverage dietary modulator for carriers of SLC2A9 risk alleles.

BMI modifies the effect: Brandstätter et al. (2008)⁷⁷ Brandstätter et al. (2008) showed in 1,869 participants that the SLC2A9 protective allele's effect on serum urate (0.30–0.35 mg/dL per copy) was significantly modified by BMI — with substantially larger effects in obese individuals compared to lean participants. This means that AA carriers with high BMI carry a compounded urate burden, while weight reduction and carbohydrate management (especially fructose) are particularly impactful for this genotype.

Practical Actions

The A allele at rs4473653 reflects reduced renal urate clearance through the SLC2A9 transport system. Because this is an independent signal from both rs11942223 and rs3733591, individuals carrying risk alleles at multiple SLC2A9 variants face an additive genetic urate burden that warrants proactive monitoring. For AA homozygotes (the most common genotype globally), the combination of elevated urate setpoint and fructose sensitivity makes sugar-sweetened beverage elimination the single most actionable dietary intervention.

Baseline serum uric acid measurement is warranted for AA carriers, especially women approaching or past menopause when estrogen's buffering effect on renal urate handling disappears. Target below 6 mg/dL (women) or 7 mg/dL (men) — above these thresholds monosodium urate crystal formation can occur in joints, tendons, and the renal pelvis.

Low-fat dairy (associated with inverse gout risk through uricosuric milk proteins), vitamin C supplementation (500 mg/day associated with ~0.5 mg/dL urate reduction), and coffee (2–4 cups/day linked to 20–40% reduced gout incidence) are useful dietary additions that have evidence across SLC2A9 risk genotypes.

Interactions

Independent from rs11942223 and rs3733591: rs4473653 (chr4:9,969,434) and rs11942223 (chr4:9,961,141) are located in separate intronic regions approximately 8 kb apart within SLC2A9. The complex LD structure of the 4p16.1 region means these tag distinct regulatory haplotypes and their effects are additive. Individuals carrying risk alleles at both variants carry compounded genetic urate burden. Similarly, rs3733591 (coding variant Arg265His) operates through a distinct mechanism (protein structure) rather than expression regulation, so all three variants can co-occur independently.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate secretion — a completely separate pathway from the renal reabsorption controlled by SLC2A9. Carrying risk alleles at rs4473653 (renal retention) and ABCG2 Q141K (reduced intestinal efflux) produces an additive elevation that can push serum urate above 7 mg/dL in individuals with otherwise moderate dietary purine intake.

Sex and menopausal status: The SLC2A9 locus shows a substantially larger effect in women (up to 6% of urate variance) than men (1.2%), driven by estrogen interaction with renal urate transporters. Women with the AA genotype at rs4473653 who are peri- or post-menopausal lose this hormonal buffer and represent the highest-risk subgroup — their risk for crossing the hyperuricemia threshold rises at menopause even without any dietary change.

Fructose and BMI: The SLC2A9 protective allele's benefit is attenuated by fructose load (especially from sugar-sweetened beverages) and amplified by higher BMI. AA homozygotes should prioritise both SSB elimination and weight management as the highest-leverage environmental modifiers of their genetically elevated urate setpoint.